Tags

Type your tag names separated by a space and hit enter

Strict glycemic control in diabetic dogs with closed-loop intraperitoneal insulin infusion algorithm designed for an artificial endocrine pancreas.
J Artif Organs. 2003; 6(1):55-63.JA

Abstract

The ultimate goal of the development of an artificial endocrine pancreas is to achieve long-term strict glycemic regulation. To establish the physiological insulin delivery route of the artificial endocrine pancreas, intraperitoneal insulin infusion may be important. For this purpose, we tried to develop a closed-loop intraperitoneal insulin infusion algorithm by analyzing the pharmacokinetics of intraperitoneal regular insulin absorption using a mathematical model. The parameters for this algorithm were calculated to simulate the plasma insulin profile after intraperitoneal insulin injection as closely as possible. To evaluate the appropriateness of this algorithm, we tried glycemic control after an oral glucose load of 2 g/kg or a meal load of 80 kcal/kg in diabetic dogs by applying the algorithm. With the use of the subcutaneous insulin lispro infusion algorithm, which we have previously reported, alloxan-induced diabetic dogs exhibited postprandial hyperglycemia and delayed hyperinsulinemia, followed by hypoglycemia after an oral glucose load of 2 g/kg. However, by using the intraperitoneal insulin infusion algorithm, excellent glycemic control (postprandial blood glucose levels of 9.1 +/- 0.8 mmol/l at 70 min and 3.8 +/- 0.3 mmol/l at 240 min, respectively) could be achieved without any associated delayed hyperinsulinemia or hypoglycemia. Glycemic excursion after a meal load of 80 kcal/kg was also controlled from 3.9 to 10.1 mmol/l. Our results confirm that the intraperitoneal insulin infusion algorithm in vivo is feasible and that this algorithm can be superior to the subcutaneous insulin lispro infusion algorithm in the regulation of blood glucose.

Authors+Show Affiliations

Department of Metabolic Medicine, Kumamoto University School of Medicine, 1-1-1 Honjo, Kumamoto 860-8556, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14598126

Citation

Matsuo, Yasuto, et al. "Strict Glycemic Control in Diabetic Dogs With Closed-loop Intraperitoneal Insulin Infusion Algorithm Designed for an Artificial Endocrine Pancreas." Journal of Artificial Organs : the Official Journal of the Japanese Society for Artificial Organs, vol. 6, no. 1, 2003, pp. 55-63.
Matsuo Y, Shimoda S, Sakakida M, et al. Strict glycemic control in diabetic dogs with closed-loop intraperitoneal insulin infusion algorithm designed for an artificial endocrine pancreas. J Artif Organs. 2003;6(1):55-63.
Matsuo, Y., Shimoda, S., Sakakida, M., Nishida, K., Sekigami, T., Ichimori, S., Ichinose, K., Shichiri, M., & Araki, E. (2003). Strict glycemic control in diabetic dogs with closed-loop intraperitoneal insulin infusion algorithm designed for an artificial endocrine pancreas. Journal of Artificial Organs : the Official Journal of the Japanese Society for Artificial Organs, 6(1), 55-63.
Matsuo Y, et al. Strict Glycemic Control in Diabetic Dogs With Closed-loop Intraperitoneal Insulin Infusion Algorithm Designed for an Artificial Endocrine Pancreas. J Artif Organs. 2003;6(1):55-63. PubMed PMID: 14598126.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Strict glycemic control in diabetic dogs with closed-loop intraperitoneal insulin infusion algorithm designed for an artificial endocrine pancreas. AU - Matsuo,Yasuto, AU - Shimoda,Seiya, AU - Sakakida,Michiharu, AU - Nishida,Kenro, AU - Sekigami,Taiji, AU - Ichimori,Shinji, AU - Ichinose,Kenshi, AU - Shichiri,Motoaki, AU - Araki,Eiichi, PY - 2003/11/5/pubmed PY - 2004/1/6/medline PY - 2003/11/5/entrez SP - 55 EP - 63 JF - Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs JO - J Artif Organs VL - 6 IS - 1 N2 - The ultimate goal of the development of an artificial endocrine pancreas is to achieve long-term strict glycemic regulation. To establish the physiological insulin delivery route of the artificial endocrine pancreas, intraperitoneal insulin infusion may be important. For this purpose, we tried to develop a closed-loop intraperitoneal insulin infusion algorithm by analyzing the pharmacokinetics of intraperitoneal regular insulin absorption using a mathematical model. The parameters for this algorithm were calculated to simulate the plasma insulin profile after intraperitoneal insulin injection as closely as possible. To evaluate the appropriateness of this algorithm, we tried glycemic control after an oral glucose load of 2 g/kg or a meal load of 80 kcal/kg in diabetic dogs by applying the algorithm. With the use of the subcutaneous insulin lispro infusion algorithm, which we have previously reported, alloxan-induced diabetic dogs exhibited postprandial hyperglycemia and delayed hyperinsulinemia, followed by hypoglycemia after an oral glucose load of 2 g/kg. However, by using the intraperitoneal insulin infusion algorithm, excellent glycemic control (postprandial blood glucose levels of 9.1 +/- 0.8 mmol/l at 70 min and 3.8 +/- 0.3 mmol/l at 240 min, respectively) could be achieved without any associated delayed hyperinsulinemia or hypoglycemia. Glycemic excursion after a meal load of 80 kcal/kg was also controlled from 3.9 to 10.1 mmol/l. Our results confirm that the intraperitoneal insulin infusion algorithm in vivo is feasible and that this algorithm can be superior to the subcutaneous insulin lispro infusion algorithm in the regulation of blood glucose. SN - 1434-7229 UR - https://www.unboundmedicine.com/medline/citation/14598126/Strict_glycemic_control_in_diabetic_dogs_with_closed_loop_intraperitoneal_insulin_infusion_algorithm_designed_for_an_artificial_endocrine_pancreas_ L2 - https://dx.doi.org/10.1007/s100470300009 DB - PRIME DP - Unbound Medicine ER -